News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Minerva Neurosciences, Inc. (NERV) To Host Second Quarter 2014 Financial Results Webcast And Conference Call


7/31/2014 10:38:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that it will release second quarter financial results after market close on Thursday, August 7, 2014. Minerva management will host a webcast and conference call the same day at 4:30 p.m. EDT to discuss the financial results and business highlights.

The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers, and by referencing conference ID number 82628409. A live webcast of the conference call will be available online from the investor relations section of the company's website at http://ir.minervaneurosciences.com/. The webcast will be archived on the company website for 30 days.

About Minerva

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. The company is developing a portfolio of first in class proprietary compounds, including lead compound MIN-101, which is in phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders.

For more information, please visit www.minervaneurosciences.com/.

CONTACT: Media Contact: Jen Ringler Berry & Company Public Relations Tel: 212-253-8881 jringler@berrypr.com Investor Contact: Renee Leck Stern Investor Relations Tel: 212-362-1200 renee@sternir.com
Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES